Clinical Trial Update: Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the Hsp90 inhibitor IPI-504 for gastrointestinal stromal tumors after failure of imatinib and sunitinib has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• IPI-504 (retaspimycin hydrochloride)

Snippet

Sponsor: Infinity Pharmaceuticals, Inc. | Conditions: Gastrointestinal Stromal Tumors | Phase 3 | Status: TERMINATED